Company news
Resverlogix Corp. news in 2009
Resverlogix Corp.'s news releases, calls and decks from 2009, newest first.
Resverlogix Announces a $5 Million Financing
December 23, 2009
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
December 22, 2009
Resverlogix Enters CAD $25 Million Standby Equity Agreement Term Sheet
December 16, 2009
Resverlogix Commences Repurchase of Convertible Debenture Debt
November 18, 2009
Resverlogix Commends Dr. William Cochrane's Induction into the Canadian Medical Hall of Fame
October 26, 2009
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
October 16, 2009
Resverlogix Appoints A. Brad Cann as Chief Financial Officer
October 13, 2009
TSX Delisting Review - Resverlogix Corp. (RVX)
October 5, 2009
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
September 29, 2009
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
September 25, 2009
Standard & Poor's annonce des modifications aux indices canadiens S&P/TSX
September 11, 2009
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
August 25, 2009
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
May 19, 2009
Resverlogix Provides Quarterly Update
April 28, 2009
Resverlogix Closes CDN $24.25M Financing
April 15, 2009
Resverlogix Announces Subscriptions for its Equity Financing
April 6, 2009
Resverlogix Confirms a US $20 Million Equity Financing Plan
March 11, 2009